Vaxxinity Inc. (VAXX)

Overview

Vaxxinity, Inc. is a pioneering biotechnology company based in the United States, specifically headquartered in Merritt Island, Florida. Founded in 2021, the company has quickly positioned itself at the forefront of biotechnological advances with a primary focus on developing vaccination product candidates for combating major public health concerns. Their research and development efforts are concentrated in the areas of neurology, cardiovascular diseases, and coronaviruses, showcasing their commitment to address some of the most challenging medical conditions affecting the global population today.

Products and Services

• UB-311 - Currently in phase 2 clinical trials, UB-311 is a vaccine targeting toxic forms of aggregated amyloid-beta (Aβ) in the brain. This product candidate is designed to combat Alzheimer's disease by aiming to reduce or eliminate the build-up of amyloid plaques that are associated with cognitive decline in patients suffering from this neurodegenerative condition.
• UB-312 - In phase 1 clinical trial, UB-312 is a vaccine that targets toxic forms of aggregated alpha-synuclein (α-synuclein) in the brain. The vaccine is developed for fighting Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy by potentially halting or reversing the accumulation of α-synuclein aggregates.
• VXX-301 - This anti-tau product candidate is currently in preclinical trials. VXX-301 is being researched for its potential application in various neurodegenerative conditions, including Alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. The vaccine aims to target and neutralize tau protein accumulations that are implicated in the progression of these conditions.
• VXX-401 - In phase 1 clinical trial, VXX-401 targets the proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease. By aiming to inhibit this enzyme, the product candidate seeks to lower low-density lipoprotein (LDL) cholesterol levels, thereby reducing the risk of cardiac events in individuals with high cholesterol.
• UB-313 - This vaccine targets the calcitonin gene-related peptide (CGRP) to combat migraines. Currently in development, UB-313 represents a novel approach to migraine prevention through the potential neutralization or inhibition of CGRP, a key peptide involved in the pathophysiology of migraines.
• UB-612 - In phase 3 clinical trials, UB-612 is a vaccine candidate designed to neutralize the SARS-CoV-2 virus. The product represents Vaxxinity, Inc.'s foray into addressing the global challenge posed by COVID-19 and potentially future coronavirus outbreaks through vaccination.